TY - JOUR
T1 - Genetic mouse models for understanding LRRK2 biology, pathology and pre-clinical application
AU - Yue, Zhenyu
N1 - Funding Information:
Funding support: NIH/NINDS grants NS060809–01, NS072359–01 and Michael J. Fox Foundation for Parkinson’s Research.
PY - 2012/1
Y1 - 2012/1
N2 - Missense mutations in Leucine-Rich Repeat kinase 2 (LRRK2) are the most common cause of inherited Parkinson's disease (PD). Elucidation of LRRK2 biology and pathophysiology is central to the development of therapeutic intervention. Our group and others have developed a number of genetic mouse models of LRRK2 utilizing different genetic approaches. These models exhibit certain PD-related pathologies (e.g. impaired dopamine transmission and tauopathies) and abnormal motor functions, providing valuable insight into potential LRRK2-mediated pathogenesis of PD. However, not surprisingly they lack of substantial neuropathology and clinical syndromes of PD. Ongoing investigation of these models has begun to shed light on LRRK2 cellular functions and pathogenic pathways and is expected to assist the identification and validation of PD drug targets. This report summarizes the recent findings in our genetic LRRK2 models and discusses their utility in understanding much needed knowledge regarding early stage (pre-symptomatic) disease progression, drug target identification, and potential application in chemical screening focused on inhibitors of kinase activity of LRRK2.
AB - Missense mutations in Leucine-Rich Repeat kinase 2 (LRRK2) are the most common cause of inherited Parkinson's disease (PD). Elucidation of LRRK2 biology and pathophysiology is central to the development of therapeutic intervention. Our group and others have developed a number of genetic mouse models of LRRK2 utilizing different genetic approaches. These models exhibit certain PD-related pathologies (e.g. impaired dopamine transmission and tauopathies) and abnormal motor functions, providing valuable insight into potential LRRK2-mediated pathogenesis of PD. However, not surprisingly they lack of substantial neuropathology and clinical syndromes of PD. Ongoing investigation of these models has begun to shed light on LRRK2 cellular functions and pathogenic pathways and is expected to assist the identification and validation of PD drug targets. This report summarizes the recent findings in our genetic LRRK2 models and discusses their utility in understanding much needed knowledge regarding early stage (pre-symptomatic) disease progression, drug target identification, and potential application in chemical screening focused on inhibitors of kinase activity of LRRK2.
KW - Genetic mouse models
KW - Lrrk2
KW - Parkinson's disease
UR - http://www.scopus.com/inward/record.url?scp=84858696035&partnerID=8YFLogxK
U2 - 10.1016/s1353-8020(11)70056-6
DO - 10.1016/s1353-8020(11)70056-6
M3 - Article
C2 - 22166428
AN - SCOPUS:84858696035
SN - 1353-8020
VL - 18
SP - S180-S182
JO - Parkinsonism and Related Disorders
JF - Parkinsonism and Related Disorders
IS - SUPPL. 1
ER -